Pfizer Inc. (NYSE:PFE) announced safety and clinical response results from the ongoing Phase 1 study (NCT03269136) for PF-06863135

The FINANCIAL -- Pfizer Inc. (NYSE:PFE) announced safety and clinical response results from the ongoing Phase 1 study (NCT03269136) for PF-06863135, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. Data from 30 patients with relapsed or refractory multiple myeloma showed manageable safety across all subcutaneous dose levels with no dose-limiting toxicities observed, and 83% of patients achieved a clinical response